S. Tjulandin

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.3K citations

Medicine, Oncology, Breast Oncology +16

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Matti Aapro, Steven M. Grunberg, George Manikhas et al. · Annals of Oncology · 2006 · 340 citations · Full text

Medicine, Oncology, Pharmacology +16

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 261 citations

Medicine, Oncology, Pharmacology +15

51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325)

E. Van Cutsem, Vladimir Moiseyenko, S. Tjulandin et al. · European Journal of Cancer Supplements · 2003 · 90 citations

Medicine, Oncology, Pharmacology +13

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso et al. · Journal of Clinical Oncology · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +13